Drug Awareness for Teenagers: Cannabis, MDMA, and New Psychoactive Substances

Why Honest Drug Education Matters

Drug education that relies on exaggeration or refuses to distinguish between levels of risk loses credibility with teenagers, who often know peers who have used substances without obvious immediate harm. Education that provides accurate, calibrated information about actual risks, including the specific vulnerability of adolescent brains, is more effective at supporting informed decision-making than blanket scare tactics.

This guide covers the substances most commonly encountered by teenagers in many countries: cannabis, MDMA (ecstasy), and new psychoactive substances (sometimes called legal highs or synthetic drugs). It presents the evidence on health risks honestly, with particular focus on why adolescents face specific and significant risks that differ from those affecting adult users.

Cannabis: The Most Widely Used Illegal Drug Among Teenagers

Cannabis is the most widely used illegal substance among teenagers globally. Its legal status varies significantly by country and even by state or region within countries, and partial or full legalisation in some jurisdictions has contributed to reduced perception of risk among young people in those areas.

Cannabis contains tetrahydrocannabinol (THC), the primary psychoactive compound, and cannabidiol (CBD), among many other compounds. The concentration of THC in cannabis products has increased substantially over recent decades, meaning that current cannabis is significantly more potent than the substance used by previous generations. This increased potency has important implications for health risks.

The health risks of cannabis use are significantly greater for teenagers than for adults for the same biological reason that applies to alcohol: the adolescent brain is still developing. THC interacts specifically with the endocannabinoid system, which plays a central role in brain development. Research shows that regular cannabis use during adolescence is associated with lasting changes in brain structure and function, including effects on memory, attention, processing speed, and executive function, that are not seen to the same degree in adults who begin using cannabis later.

The mental health risks of cannabis are particularly significant and are among the most clearly documented harms. Regular cannabis use is associated with increased rates of anxiety and depression. For individuals with a genetic predisposition to psychotic disorders including schizophrenia, cannabis use during adolescence substantially increases the risk of developing psychosis. High-potency cannabis products carry greater psychosis risk than lower-potency ones. These risks are not theoretical: a significant proportion of young people presenting to mental health services with psychotic symptoms have a history of heavy cannabis use.

Dependency can develop with regular cannabis use. Cannabis use disorder is a recognised clinical condition affecting a proportion of regular users. Withdrawal symptoms, while not as severe as with alcohol or opioids, include irritability, sleep disruption, anxiety, and reduced appetite. Teenagers who depend on cannabis to manage anxiety or other emotional difficulties often find that the substance maintains the underlying condition rather than treating it.

Cannabis and driving carries serious risks. Cannabis impairs reaction time, spatial judgement, and hazard perception. The combination of cannabis and alcohol impairs driving more severely than either substance alone. Importantly, unlike alcohol, there is no reliable way for a driver to assess their own impairment level, and the impairing effects can persist for several hours after use.

MDMA: Risks in a Social Drug

MDMA (3,4-methylenedioxymethamphetamine), commonly known as ecstasy or molly, is used primarily in social and party contexts and is among the most commonly used recreational drugs by older teenagers and young adults at festivals and clubs worldwide. Understanding its actual risk profile is important for informed harm reduction.

MDMA causes the release of serotonin, dopamine, and noradrenaline, producing feelings of emotional closeness, euphoria, and increased energy. Acute risks include hyperthermia (dangerous overheating, which is the primary cause of MDMA-related deaths), hyponatraemia (dangerous low sodium levels caused by drinking excessive water in response to thirst), and cardiovascular stress. These acute risks are increased by dancing in hot environments, poor fluid management, and mixing with other substances.

The serotonin system effects of MDMA are concerning for developing brains. Animal research and some human neuroimaging studies suggest potential long-term effects on serotonergic systems with repeated use, though the degree of risk in humans remains an active research area. What is clearer is that the risk of acute harms is higher in adolescents, who metabolise the substance differently from adults, and that mixing MDMA with other substances (including alcohol, cannabis, and particularly other stimulants or antidepressants) significantly increases risk.

Purity and content of street-sold MDMA varies enormously. Pills sold as ecstasy may contain little or no MDMA and instead contain more dangerous substances including methamphetamine, cathinones, or novel psychoactive substances. Drug checking services, where available, allow testing of substances before use and have identified many dangerous adulterants in pills sold as MDMA.

New Psychoactive Substances

New psychoactive substances (NPS), previously described as legal highs or synthetic drugs, are a chemically diverse and rapidly evolving group of substances designed to mimic the effects of established drugs while initially evading legal prohibition. They represent a particular risk because their effects, toxicity, and interactions are poorly understood compared to more established substances.

Synthetic cannabinoids (sometimes called spice or K2) are one of the most widely used and most dangerous categories of NPS. Despite their name, they are not related to natural cannabis and their effects can be dramatically more severe: psychosis, seizures, cardiovascular emergencies, and death have all been associated with synthetic cannabinoid use in ways that are rare with natural cannabis. They are frequently used by young people who seek to avoid drug testing or who believe they are safer than cannabis because of their historical legal status.

The fundamental problem with NPS is the absence of safety data. Every new compound that emerges has essentially never been tested in humans outside of uncontrolled recreational use. The harms of established drugs, though real, are at least reasonably well characterised. The harms of NPS are genuinely unknown until they become apparent through emergency department presentations and deaths.

Having These Conversations

Effective drug conversations with teenagers are honest, calibrated, specific, and focused on the developmental reasons why these risks are particularly significant for young people rather than adults. Conversations that provide accurate information, acknowledge genuine uncertainty, and focus on the adolescent-specific biology, are more credible and more effective than those that rely on exaggeration or scare tactics. Young people who are given honest information are better equipped to make informed decisions than those whose education has been so distorted by exaggeration that they cannot trust any of it.